Hygieia Receives Notice For Key Patent Covering Diabetes Insulin Guidance System
ANN ARBOR — Hygieia Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims broadly covering the company’s Diabetes Insulin Guidance System technology.
The patent application, entitled “System for Optimizing a Patient’s Insulin Dosage Regimen” relates to Hygieia’s unique methods of automatically adjusting a diabetic patient’s insulin dosage as needed to achieve a better glycemic balance of lowered hemoglobin A1C, as well as reduced hypoglycemia frequency.
“DIGS is the first technology to uniquely provide insulin users with the means to attain good blood glucose control along with the important safety requirement of avoiding hypoglycemia,” said Eran Bashan, Hygieia CEO. “This patent allowance greatly strengthens Hygieia’s commercial position and boosts our roll out efforts in the United Kingdom, where our d-Nav™ Diabetes Insulin Guidance System product is currently available.”
Last fall, the d-Nav Diabetes Insulin Guidance System, Hygieia’s first commercial product to incorporate DIGS technology, was granted a CE Mark, and the South Eastern Health and Social Care Trust’s Ulster Hospital diabetes centre in Belfast, Northern Ireland led by Dr. Roy Harper, began using d-Nav with its patients. This month, The Heart of England Foundation Trust began using d-Nav at the Heartlands Hospital diabetes centre in Birmingham, under the direction of Prof. Martin Stevens.
Hygieia, Inc. is a diabetes health care company founded in Ann Arbor to commercialize its proprietary Diabetes Insulin Guidance System technology. Hygieia’s first handheld medical device, the d-Nav Diabetes Insulin Guidance System, is designed to improve diabetes care delivery. d-Nav makes it feasible for millions of insulin users to be more effectively and efficiently treated. Hygieia’s d-Nav is now available to patients in select diabetes centers in the United Kingdom. Visit http://www.hygieia.com or email firstname.lastname@example.org for more information.
The United States Food and Drug Administration has neither approved nor cleared the d-Nav Diabetes Insulin Guidance System for distribution in the United States.